TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29717337

Group type: EXPERIMENTAL
Intervention: Sprint interval training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both exercise modes
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 27783027

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care program
Number of subjects: 140
Study: 25876341

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of flunarizine hydrochloride capsules (5mg, once every night for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of flunarizine hydrochloride capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy and medicine group
Number of subjects: 60
Study: 21563952

Group type: EXPERIMENTAL
Intervention: Induction phase (no oral hygiene for 21 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resolution phase (home care reinstated until 35 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline levels of salivary IL‐6 and IL‐8
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High levels of IL‐6 and MMP‐1 at baseline
Number of subjects: 30
Study: 20463812

Group type: EXPERIMENTAL
Intervention: Azithromycin (a macrolide antibiotic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 18677972

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (300 mg/day)
Number of subjects: 10
Study: 15657324

Group type: EXPERIMENTAL
Intervention: 6-month quality improvement intervention (n = 211)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Usual care (n = 207)
Number of subjects: 418
Study: 12562485

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with fentanyl 1 microg.kg(‐1) (group BF)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with midazolam 50 microg.kg(‐1) (group BM)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (group B)
Number of subjects: 75
Study: 10100652

Group type: EXPERIMENTAL
Intervention: 3‐msec pulsed ruby laser at fluences from 10 to 40 J/cm2
Number of subjects: 24
Study: 8894860

Group type: EXPERIMENTAL
Intervention: 1% lignocaine plus 1500 IU hyaluronidase
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1% lignocaine
Number of subjects: 33
Study: 2005233

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4% stannous fluoride gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (1.25% fluoride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study: 7046500

Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ascorbic acid 100 mg
Number of subjects: 30
Study: 31382932

Group type: EXPERIMENTAL
Intervention: Stepped-Care Pathway (SCP)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Online Cognitive Behavioral Therapy (CBT)
Number of subjects: 1400
Study: 29191450

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 1.1 mL (275 mg) of hydroxyprogesterone caproate (HPC) administered using an autoinjector
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intramuscular injection of 1 mL (250 mg) of hydroxyprogesterone caproate (HPC)
Number of subjects: 90
Study: 26611244

Group type: EXPERIMENTAL
Intervention: Uncinectomy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Balloon Sinuplasty
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Smoking (as a factor)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methylene Blue Test
Number of subjects: 29
Study: 24061764

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 20814889

Group type: EXPERIMENTAL
Intervention: Self-assembled peptide nanospheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aβ(1-42) peptide
Number of subjects: 0
Study: 20079177

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 65

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 65
Study: 17201545

Group type: EXPERIMENTAL
Intervention: More information about others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambiguity (lack of information)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge about others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre- and post-date data from online daters
Number of subjects: 0
Study: 15500103

Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution (1,000 ml, n=8)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch (1,000 ml, n=9)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: No preload (n=10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Emergency group (n=5)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no preload)
Number of subjects: 32
Study: 11474722

Group type: EXPERIMENTAL
Intervention: Participants who believed in catharsis and venting anger
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mood-freezing pill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with high anger-out tendencies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire data from Studies 3 and 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures from Study 5
Number of subjects: 0
Study: 9558806

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eclectic treatment programs
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comprehensive clinical treatment including hypnosis
Number of subjects: 8
Study: 7894340

Group type: EXPERIMENTAL
Intervention: T3 (30 micrograms/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3308390

Group type: EXPERIMENTAL
Intervention: Minaprine (100 mg b.i.d.)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Imipramine (50 mg b.i.d.)
Number of subjects: 104
Study: 31892277

Group type: EXPERIMENTAL
Intervention: Dynamic resistance exercise with an elastic resistance band
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isometric contraction exercises
Number of subjects: 70
Study: 28986271

Group type: EXPERIMENTAL
Intervention: Echocardiography (Echo) and cardiac magnetic resonance imaging (cMRI) assessments
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: cMRI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Echocardiography (Echo)
Number of subjects: 48
Study: 27530656

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 824

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study: 25004024

Group type: EXPERIMENTAL
Intervention: Certoparin in patients with pulmonary embolism
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients with pulmonary embolism
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Certoparin in patients without pulmonary embolism
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients without pulmonary embolism
Number of subjects: 1653
Study: 20859765

Group type: EXPERIMENTAL
Intervention: Time Limited Care‐Coordination (TLC), an eight‐week co‐occurring disorders intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Matched Attention (MA) control condition in the form of health education sessions
Number of subjects: 102
Study: 19804963

Group type: EXPERIMENTAL
Intervention: NIV+O(2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: O(2) alone
Number of subjects: 34
Study: 18476954

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study: 16120455

Group type: EXPERIMENTAL
Intervention: Direct-mail communications with phone follow-up
Number of subjects: 424

Group type: COMPARATOR
Intervention: Direct-mail communications without phone intervention (placebo messages)
Number of subjects: 424
Study: 12770794

Group type: EXPERIMENTAL
Intervention: HFE S65C mutation
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: HFE C282Y mutation
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: HFE mutations (C282Y, H63D, S65C)
Number of subjects: 218
Study: 11263272

Group type: EXPERIMENTAL
Intervention: Garlicin injection (60 mg/day for 10 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nitroglycerine (control group)
Number of subjects: 34
Study: 8644686

Group type: EXPERIMENTAL
Intervention: Crackers with cream cheese
Number of subjects: 15

Group type: COMPARATOR
Intervention: Crackers with nonfat cream cheese
Number of subjects: 15

Group type: COMPARATOR
Intervention: Crackers alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 15
Study: 2000846

Group type: EXPERIMENTAL
Intervention: Imprisonment longer than 28 days
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Household crowding
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Direct smoking at home
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Passive smoking at home
Number of subjects: 600
Study: 6337669

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional treatment (medical measures, modified splenectomy, oesophagogastric devascularization)
Number of subjects: 108
Study: 30576449

Group type: EXPERIMENTAL
Intervention: Virtual Chromoendoscopy (VCE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Chromoendoscopy (CE)
Number of subjects: 60
Study: 30566441

Group type: EXPERIMENTAL
Intervention: Supported Self-help Preventive Cognitive Therapy (S-PCT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 248
Study: 27172435

Group type: EXPERIMENTAL
Intervention: Immediate treatment with clomiphene from PPCOS II trial (N = 187)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Delayed treatment with clomiphene after oral contraceptive pretreatment in OWL PCOS trial (N = 142)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Deferred clomiphene treatment preceded by lifestyle modification (N = 129)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Deferred clomiphene treatment preceded by combined treatment (N = 129)
Number of subjects: 329
Study: 24589316

Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 21515562

Group type: EXPERIMENTAL
Intervention: 532 nm continuous‐wave Nd:YAG laser pretreatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard pulsed 1064 nm Nd:YAG laser iridotomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (sequential and standard treatment)
Number of subjects: 30
Study: 20211953

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study: 17588715

Group type: EXPERIMENTAL
Intervention: TV annuloplasty with the MC3 ring
Number of subjects: 136
Study: 16182733

Group type: EXPERIMENTAL
Intervention: 14-cm 4.8-F double J stent with anti-reflux device (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 14-cm 4.8-F double J stent without anti-reflux device (group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 44
Study: 14644054

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and family treatment components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated treatment approach
Number of subjects: 0
Study: 10379447

Group type: EXPERIMENTAL
Intervention: Silver-impregnated central venous catheter
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control catheters (no antimicrobial activity)
Number of subjects: 165
Study: 8884873

Group type: EXPERIMENTAL
Intervention: 4 IU/ml in a bicarbonate buffer dissolved in 0.9% benzyl alcohol (approximately 1.37 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5.9 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 2 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 11.7 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 4 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5.9 IU/ml
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 11.7 IU/ml
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4 IU/ml
Number of subjects: 18
Study: 1676318

Group type: EXPERIMENTAL
Intervention: Cabergoline (1 mg, two 0.5 mg tablets and one placebo tablet within 27 hours after delivery, then placebo twice daily for 14 days)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg, two placebo tablets within 27 hours after delivery, then 2.5 mg twice daily for 14 days)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 272
Study: 6500678

Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction (from approximately 110 to 40 mEq per day)
Number of subjects: 33
Study: 29721010

Group type: EXPERIMENTAL
Intervention: Active ihPAS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control ihPAS
Number of subjects: 20
Study: 28073985

Group type: EXPERIMENTAL
Intervention: Maternal vaccination during pregnancy (part of a randomized controlled trial of influenza vaccination)
Number of subjects: 3483
Study: 26186449

Group type: EXPERIMENTAL
Intervention: Fruit smoothie
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 81
Study: 23360656

Group type: EXPERIMENTAL
Intervention: Clary oil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Almond oil (control)
Number of subjects: 34
Study: 21092293

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - specific PFTs selected according to protocol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control Group (CG) - all PFTs ordered by lung specialist
Number of subjects: 179
Study: 17993594

Group type: EXPERIMENTAL
Intervention: Losartan (2 microg/l)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitro-L-arginine (NLA, 10 mM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan + NLA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study: 16731213

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study: 12601840

Group type: EXPERIMENTAL
Intervention: Measurement of serum activin A
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Measurement of serum inhibin A
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Activin A at cut-off value of 1.7 MoM
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhibin A at cut-off value of 1.8 MoM
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both activin A and inhibin A elevated
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both hormone markers unaltered
Number of subjects: 58
Study: 11099790

Group type: EXPERIMENTAL
Intervention: TIVADs
Number of subjects: 126
Study: 8750077

Group type: EXPERIMENTAL
Intervention: Preference assessment and simple, low‐effort treatment procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chronic training needs group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Analysis of characteristics of the two groups
Number of subjects: 15
Study: 1487623

Group type: EXPERIMENTAL
Intervention: Bromperidol decanoate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 47
Study: 6437707

Group type: EXPERIMENTAL
Intervention: Constant rate enteral nutrition (CREN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractioned enteral nutrition (FEN)
Number of subjects: 0
Study: 31776122

Group type: EXPERIMENTAL
Intervention: Short term exposure to PM2.5 (1 µg/m3 increase)
Number of subjects: 95277169
Study: 29396118

Group type: EXPERIMENTAL
Intervention: Primrose intervention (appointments ≤12 with a trained primary care professional)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Treatment as usual (feedback of screening results only)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Primrose intervention
Number of subjects: 327

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 327
Study: 27120082

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg single dose on the evening prior to surgery; 40 mg on the morning of surgery; three further doses of 40 mg on the evenings of postoperative days 0, 1, and 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Atorvastatin and Placebo
Number of subjects: 200
Study: 24660950

Group type: EXPERIMENTAL
Intervention: Peer-facilitated recovery groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated recovery groups
Number of subjects: 24
Study: 22356933

Group type: EXPERIMENTAL
Intervention: Symbiotic shake containing Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides, 200 mL daily for 30 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo shake without symbiotic bacteria, 200 mL daily for 30 days.
Number of subjects: 20
Study: 20606661

Group type: EXPERIMENTAL
Intervention: Certolizumab (biologic therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17256746

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) added to LAM (n = 28)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) monotherapy (n = 14)
Number of subjects: 42
Study: 16398422

Group type: EXPERIMENTAL
Intervention: Integrated traditional and Western medicine (ITWM)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 324
Study: 12197792

Group type: EXPERIMENTAL
Intervention: Manipulative props
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2-dimensional food portion visuals
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both measurement aids
Number of subjects: 54
Study: 9526923

Group type: EXPERIMENTAL
Intervention: Quality of care dimensions including access, appropriateness, technical quality, and the art of care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance guidelines developed by the U.S. Food and Drug Administration and various dental specialties.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical outcomes of treatment and health and well-being measures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality measurement aspects within a quality assurance program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role of the periodontist in quality of care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Managed care implications for quality of periodontal treatment and patient management.
Number of subjects: 0
Study: 7652682

Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 159

Group type: COMPARATOR
Intervention: Circular stapled anastomosis
Number of subjects: 159
Study: 2527699

Group type: EXPERIMENTAL
Intervention: Memory group using meters with inbuilt memories linked to a computer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional group using diaries to record self‐monitoring meter‐read results
Number of subjects: 18
Study: 11277

Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31248644

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 125
Study: 28094841

Group type: EXPERIMENTAL
Intervention: Pracinostat
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26467530

Group type: EXPERIMENTAL
Intervention: Structured follow-up by the GP over a 6-month period with a minimum of five consultations.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Structured follow-up by the GP
Number of subjects: 202
Study: 23434517

Group type: EXPERIMENTAL
Intervention: PAR ablation
Number of subjects: 86

Group type: COMPARATOR
Intervention: PV isolation
Number of subjects: 86
Study: 19956980

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg i.v. every 12 h for two doses, followed by 300 mg BID)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole (200 mg i.v. twice daily for 2 days, followed by 200 mg i.v. daily)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 123
Study: 19375108

Group type: EXPERIMENTAL
Intervention: 300 mg pentosan polysulfate sodium per day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 128
Study: 17343008

Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Recipe (YHR) combined with polyene phosphatidycholine capsule (PPC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyene phosphatidycholine capsule (PPC) alone
Number of subjects: 80
Study: 16297506

Group type: EXPERIMENTAL
Intervention: Standard diet plus two high-protein/energy supplements containing additional arginine (9 g), vitamin C (500 mg) and zinc (30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard hospital diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard diet plus two high-protein/energy supplements
Number of subjects: 16
Study: 12235448

Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Garlic oil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Panax ginseng
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 12
Study: 9842809

Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1.5 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rocuronium (Roc) 1.2 mg/kg
Number of subjects: 26